Summarized by Masters of Longevity from Longevity Technology.
A 16‑week, ~40‑patient phase 2 trial will test inhaled treprostinil safety and tolerability.
Key Takeaways
- The trial is non‑definitive and cannot prove efficacy.
- Exercise capacity and NT‑proBNP are secondary endpoints.
- Soft‑mist delivery may reduce cough and bronchospasm.
